Voyager Reports Third Quarter 2024 Financial and Operating Results
Provided By GlobeNewswire
Last update: Nov 12, 2024
- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 -
Read more at globenewswire.com
